Home » Topics » BioWorld Science

BioWorld Science
RSS

Prescient presents promising interim phase Ib data for PTX-200 in ovarian cancer

Dec. 13, 2019

Positive interim safety data presented from ongoing phase Ib/IIa study of ATYR-1923

Dec. 13, 2019

Phase Ib data for carfilzomib plus chemotherapy in children with refractory ALL

Dec. 13, 2019

EGFL7 as a new therapeutic target in AML

Dec. 13, 2019

TDP-43-mediated splicing repression as a therapeutic target for ALS-FTD

Dec. 13, 2019

Phase I data presented for the novel M1 mAChR modulator VU-319

Dec. 13, 2019

Manageable safety and activity seen with GDC-0077 combination treatments in phase Ib study

Dec. 13, 2019

Improbability research yields path to HIV vaccine

Dec. 13, 2019

Emergex advances early development of vaccine candidate against F. tularensis

Dec. 12, 2019

Transgene opens enrollment in phase I study of TG-4050 for ovarian cancer

Dec. 12, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026